Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2CTx-1301 is the First, True, Once-Daily Stimulant Medication to ...

CING READ THE FULL CING RESEARCH REPORT Since the report of third quarter results, Cingulate, Inc. (NASDAQ:CING) has executed ...

Cingulate (CING) released Phase 3 safety data for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD.

Researchers have discovered how specific brain circuits process empathy, showing that witnessing others in pain activates the ...

Cingulate (NASDAQ:CING – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They ...

Cingulate Inc. submitted CTx-1301 Phase 3 safety data to the FDA, preparing for a Pre-NDA meeting on April 2, 2025. Cingulate Inc. announced the submission of Phase 3 safety data for its ADHD ...

Three regions, in particular, play key roles: the anterior cingulate cortex, the prefrontal cortex and the insula. The anterior cingulate cortex and the prefrontal cortex are part of a network ...

The subtleties involved here reflect the fact that the brain’s dizzying complexity means it’s rarely possible to draw simple ...

A research team has uncovered key insights into how the brain processes others' distress. Using miniature endoscopic calcium imaging, the researchers identified specific neural ensembles in the ...

KANSAS CITY, Kan., March 04, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery ...

Having a word “on the tip of the tongue” has happened to all of us. Behind this everyday phenomenon lie complex brain mechanisms.